An insurance benefit that provides percutaneous coronary intervention patients with a discharge supply of antiplatelet medication could result in cost savings for insurers.
Michael P. Dorsch, PharmD, MS
Advertisement
Articles by Michael P. Dorsch, PharmD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
3
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
4
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
5